771 completed, 344 unknown, 265 terminated, 140 withdrawn. 1639 Phase 2, 306 Phase 3, 281 Phase 1.
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO Low anticoagulation dose of argatroban and enoxaparin during ECMO, Standard anticoagulation dose of argatroban and enoxaparin during ECMO - Pneumonia, Heart Failure | Phase 2 | Not yet recruiting | University Hospital Ostrava | 200 | 2027-01-01 | 2026-04-02 |
| Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia colistimethate sodium, 0.9% Saline - Ventilator Associated Pneumonia | Phase 2 / Phase 3 | Not yet recruiting | University Hospital Fattouma Bourguiba | 400 | 2027-01-01 | 2026-10-08 |
| Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19 | Phase 1 / Phase 2 | Not yet recruiting | Kimera Labs Inc. | 64 | 2027-01-01 | 2026-06-24 |
| Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 30 | 2026-12-30 | 2026-10-16 |
| CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 38 | 2026-12-01 | 2026-07-24 |
| SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction Valacyclovir, Celecoxib, Paxlovid - Post-acute Sequelae of COVID-19, Long COVID | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 150 | 2026-10-20 | 2026-10-28 |
| Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia Inhaled levofloxacin, Standard-of-care / Usual care - Community-acquired Pneumonia, CAP | Phase 2 / Phase 3 | Active not recruiting | Copenhagen Respiratory Research | 460 | 2026-10-08 | 2026-11-05 |
| Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Christiana Franke | 138 | 2026-10-01 | 2026-07-20 |
| Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome VYD2311, Placebo - Long COVID, COVID-19 (SARS-CoV-2 Infection) | Phase 2 | Not yet recruiting | Invivyd, Inc. | 130 | 2026-10-01 | 2026-10-27 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Recruiting | ModernaTX, Inc. | 300 | 2026-09-04 | 2026-10-29 |
| " Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation " Amikacin, Standard of care - Pneumonia, Bacterial, Extracorporeal Membrane Oxygenation | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 26 | 2026-08-10 | 2026-08-13 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia NRICM102, Placebo, Intravenous Antibiotic - Mild to Moderate, Community-Acquired Pneumonia (CAP) | Phase 2 | Not yet recruiting | National Research Institute of Chinese Medicine, Ministry of Health and Welfare | 150 | 2026-06-01 | 2026-05-13 |
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure agenT-797, Placebo, Standard of Care (SOC) - Pneumonia | Phase 2 | Recruiting | MiNK Therapeutics | 90 | 2026-05-26 | 2026-06-26 |
| Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID | Phase 2 | Recruiting | ParagonClinicals Inc. | 82 | 2026-05-20 | 2026-06-04 |
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus | Phase 2 | Enrolling by invitation | Leading Edge Clinic | 20 | 2026-05-15 | 2026-05-13 |
| Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial Microbiome-guided inhaled antibiotic prophylaxis, Placebo - Critical Illness, Mechanical Ventilation | Phase 2 | Not yet recruiting | University of Calgary | 70 | 2026-05-01 | 2026-03-11 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Sonlicromanol in Post-COVID Sonlicromanol, Placebo - Post COVID Condition | Phase 2 | Recruiting | Michele van Vugt | 80 | 2026-04-03 | 2026-08-18 |
Showing 20 of 1639. Sign in to see all of them.
COVID-19 (1391) · Coronavirus Infections (233) · Post-Acute COVID-19 Syndrome (93) · Respiratory Distress Syndrome (83) · Severe Acute Respiratory Syndrome (65) · Pneumonia, Ventilator-Associated (42) · Virus Diseases (38) · Cytokine Release Syndrome (37) · Pneumonia, Viral (36) · Community-Acquired Pneumonia (29) · Respiratory Insufficiency (26) · Infections (25) · Respiratory Tract Infections (22) · Pneumonia, Bacterial (20)
Respiratory Tract Diseases (1631) · Respiratory Tract Infections (1617) · Infections (1614) · Lung Diseases (1605) · RNA Virus Infections (1461) · Nidovirales Infections (1457) · Coronaviridae Infections (1456) · Virus Diseases (1435) · Pneumonia, Viral (1426) · Coronavirus Infections (1228) · Pathological Conditions, Signs and Symptoms (291) · Pathologic Processes (259) · Disease Attributes (173) · Respiration Disorders (110)
Standard of Care (82) · Hydroxychloroquine (64) · Saline Solution (51) · Sodium Chloride (51) · BNT162 Vaccine (39) · Ivermectin (27) · Azithromycin (26) · 2019-nCoV Vaccine mRNA-1273 (24) · Ritonavir (24) · remdesivir (18) · nitazoxanide (17) · favipiravir (16) · COVID-19 Serotherapy (15) · COVID-19 Vaccines (15) · Ascorbic Acid (14)
National Institute of Allergy and Infectious Diseases (NIAID) (18) · Sinocelltech Ltd. (17) · Sorrento Therapeutics, Inc. (15) · BioNTech SE (13) · Pfizer (13) · Assistance Publique - Hôpitaux de Paris (11) · Novavax (11) · Stanford University (10) · Washington University School of Medicine (10) · ModernaTX, Inc. (9) · AstraZeneca (8) · GlaxoSmithKline (8) · The University of Hong Kong (8) · ANRS, Emerging Infectious Diseases (7) · D'Or Institute for Research and Education (7)
United States (570) · Brazil (106) · Spain (106) · China (96) · France (82) · Canada (66) · United Kingdom (65) · Germany (61) · Italy (59) · Mexico (58) · Russia (55) · South Africa (55) · Argentina (43) · Belgium (41) · South Korea (34)
Mike Royal, MD (14) · Mikhail Samsonov (5) · Fengcai Zhu, Doctor (4) · Ivan FN Hung, MD FRCP (4) · Bill Arana (3)
PMID 34473343, PMID 35713300, PMID 34013969, PMID 35244208, PMID 36734509, PMID 37162745, PMID 34658014, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 32192578, PMID 32788708, PMID 40592258, PMID 29515037, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33044747, PMID 33754144, PMID 36700518, PMID 37489818, PMID 41720282, PMID 15141377, PMID 23053510, PMID 23208422, PMID 25030060, PMID 29859173, PMID 31978293, PMID 31986257, PMID 32020029, PMID 32085846, PMID 32091533, PMID 32125455, PMID 32150618, PMID 32167524, PMID 32171740, PMID 32187464, PMID 32219428, PMID 32240634, PMID 32257537, PMID 32658300, PMID 32896291, PMID 33240091, PMID 33306989, PMID 33388170
2023 (9), 2019 (3), 2025 (3), P30CA033572 (3), 2008 (2), 2014 (2), R01NR007652 (2), UL1TR001412 (2), 1ZIDES102465 (1), 2015 (1), 2016 (1), 2017 (1), 272201800011C-P00005-9999-1 (1), 2UG1CA189859-06 (1), 3UH3DK114920-04S2 (1)